REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Regenxbio outlines 2026 Duchenne, wet AMD, and diabetic retinopathy milestones while targeting pivotal data releases [Seeking Alpha]
REGENXBIO (RGNX) had its "overweight" rating reaffirmed by Morgan Stanley.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGNX